Auricular Acupuncture and Hot Flashes During Adjuvant Endocrine Therapy
OhrHit
Effect and Effectiveness of Auricular Acupuncture in Improving Hot Flashes During Adjuvant Endocrine Therapy in Women With Breast Cancer: A Randomized Controlled Study
1 other identifier
interventional
107
1 country
2
Brief Summary
With this clinical trial we investigate whether auricular acupuncture during adjuvant endocrine therapy has an improving effect on hot flashes, which are often perceived as psychologically and physically stressful in self-assessment of women with breast cancer. Empirical studies indicate that body acupuncture has positive effects on hot flashes. As auricular acupuncture offers a number of advantages over body acupuncture, a three-armed randomised controlled research design is being used to investigate whether hot flashes caused by endocrine therapy are also reduced by ear acupuncture. Balanced ear acupuncture will be compared with NADA ear acupuncture in terms of efficacy and effectiveness. In addition, the effects of the two forms of therapy on the patients' individual quality of life, fatigue, stress perception and sleep quality will be analysed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2024
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 12, 2024
CompletedFirst Posted
Study publicly available on registry
April 16, 2024
CompletedStudy Start
First participant enrolled
June 17, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 8, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 8, 2025
CompletedDecember 15, 2025
August 1, 2025
1.2 years
April 12, 2024
December 6, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
subscale somato-vegetative symptoms of the Menopause Rating Scale (MRS)
measure for hot flashes, from minimum 0 to maximum 4, with the maximum being the worst outcome
Baseline, end of the intervention (6 weeks after the beginning), three months follow-up
Secondary Outcomes (9)
Menopause Rating Scale (MRS) total score
Baseline, end of the intervention (6 weeks after the beginning), three months follow-up
Psychological symptoms and urogenital symptoms subscales of the MRS
Baseline, end of the intervention (6 weeks after the beginning), three months follow-up
functional assessment of cancer therapy - breast (FACT-B)
Baseline, end of the intervention (6 weeks after the beginning), three months follow-up
perceived stress questionnaire (PSQ)
Baseline, end of the intervention (6 weeks after the beginning), three months follow-up
insomnia severity index (ISI)
Baseline, end of the intervention (6 weeks after the beginning), three months follow-up
- +4 more secondary outcomes
Study Arms (3)
NADA auricular acupuncture
ACTIVE COMPARATORPatients in one intervention group are treated twice a week for five weeks with balanced ear acupuncture.The data sets of those subjects who received at least eight balanced ear acupuncture treatments will be compared with those who got NADA acupuncture and those who were not treated.
balanced auricular acupuncture
ACTIVE COMPARATORPatients in the other intervention group are treated twice a week for five weeks with NADA ear acupuncture. The data sets of those subjects who received at least eight NADA ear acupuncture treatments will be compared with those who got balanced ear acupuncture and those who were not treated.
wait list control
NO INTERVENTIONControl group: At the end of the 3-month follow-up, the patients in the control group received 10 ear acupuncture treatments in a group setting.
Interventions
two auricular acupuncture methods are compared with each other and with no treatment
Eligibility Criteria
You may qualify if:
- histologically confirmed diagnosis of non-metastatic hormone receptor-positive breast CA (TNM stage I-III) under adjuvant endocrine therapy
- hot flashes, measured with the MRS (Menopause Rating Scale)
- willingness to participate in the study and signed informed consent
You may not qualify if:
- ongoing or planned chemotherapy, radiotherapy, follow-up treatment or reconstructive plastic surgery during the study period
- severe physical or psychopharmacologically treated psychiatric comorbidity, due to which a patient is unable to participate in the study
- pregnancy
- participation in other clinical trials with behavioural, psychological or complementary medicine, psychological or complementary medical interventions
- regular use of barbiturates, antidepressants, abuse of drugs and/or alcohol
- ongoing acupuncture treatment
- lack of ability to complete the questionnaires independently
- operations or infections in the area to be acupunctured
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kliniken Essen-Mittelead
- Karl and Veronica Carstens Foundationcollaborator
Study Sites (2)
Evang. Kliniken Essen-Mitte gGmbH
Essen, Essen, Germany
Evang. Kliniken Essen-Mitte gGmbH
Essen, Germany
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 12, 2024
First Posted
April 16, 2024
Study Start
June 17, 2024
Primary Completion
September 8, 2025
Study Completion
September 8, 2025
Last Updated
December 15, 2025
Record last verified: 2025-08